234 related articles for article (PubMed ID: 22498504)
1. [Safety and efficacy of a new preservative-free levocabastine ophthalmic solution (Levofree®) using the conjunctival provocation test].
Allaire C; Siou-Mermet R; Bassols A
J Fr Ophtalmol; 2012 Sep; 35(7):491-8. PubMed ID: 22498504
[TBL] [Abstract][Full Text] [Related]
2. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
4. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
Netland PA; Leahy C; Krenzer KL
Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
Fujishima H; Ohashi Y; Takamura E
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
[TBL] [Abstract][Full Text] [Related]
6. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
Macejko TT; Bergmann MT; Williams JI; Gow JA; Gomes PJ; McNamara TR; Abelson MB;
Am J Ophthalmol; 2010 Jul; 150(1):122-127.e5. PubMed ID: 20488431
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of three antiallergic eyedrops in a specific conjunctival provocation test: mequitazine, levocabastine and dexamethasone].
Richard C; Bibas P; Lablache-Combier M; Allaire C
J Fr Ophtalmol; 2005 Mar; 28(3):244-50. PubMed ID: 15883488
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of levocabastine hydrochloride ophthalmic suspension in the conjunctival allergen challenge test in Japanese subjects with seasonal allergic conjunctivitis.
Takamura E; Nomura K; Fujishima H; Fukagawa K; Satake Y; Fukada Y; Sawa M; Uchida E
Allergol Int; 2006 Jun; 55(2):157-65. PubMed ID: 17075252
[TBL] [Abstract][Full Text] [Related]
9. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
[TBL] [Abstract][Full Text] [Related]
10. Effect of antihistamine eye drops on the conjunctival provocation test with Japanese cedar pollen allergen.
Dake Y; Enomoto T; Cheng L; Enomoto K; Shibano A; Ikeda H; Yoda S; Yajin S; Sakota T; Yamanishi E
Allergol Int; 2006 Dec; 55(4):373-8. PubMed ID: 17130679
[TBL] [Abstract][Full Text] [Related]
11. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis.
Giede C; Metzenauer P; Petzold U; Ellers-Lenz B
Curr Med Res Opin; 2000; 16(3):153-63. PubMed ID: 11191004
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of allergic conjunctivitis by thermography.
Hara Y; Shiraishi A; Yamaguchi M; Kawasaki S; Uno T; Ohashi Y
Ophthalmic Res; 2014; 51(3):161-6. PubMed ID: 24603108
[TBL] [Abstract][Full Text] [Related]
13. The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis.
Fujishima H; Fukagawa K; Tanaka M; Uchio E; Takamura E; Nakagawa Y; Miyazaki D; Fukushima A; Okamoto S; Yokoi N
Ophthalmologica; 2008; 222(4):232-9. PubMed ID: 18463425
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
[TBL] [Abstract][Full Text] [Related]
15. The early efficacy of topical levocabastine in patients with allergic conjunctivitis.
Fujishima H; Fukagawa K; Takano Y; Okamoto S; Nakagawa Y; Uchio E; Yokoi N; Fukushima A; Takamura E
Allergol Int; 2006 Sep; 55(3):301-3. PubMed ID: 17075271
[TBL] [Abstract][Full Text] [Related]
16. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis.
Mortemousque B; Bourcier T; Khairallah M; Messaoud R; Brignole-Baudouin F; Renault D; Rebika H; Brémond-Gignac D;
J Fr Ophtalmol; 2014 Jan; 37(1):1-8. PubMed ID: 24388379
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
Abelson MB; Spangler DL; Epstein AB; Mah FS; Crampton HJ
Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
Friedlaender MH; Harris J; LaVallee N; Russell H; Shilstone J
Ophthalmology; 2000 Dec; 107(12):2152-7. PubMed ID: 11097587
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model.
Abelson MB; Chapin MJ; Kapik BM; Shams NB
Arch Ophthalmol; 2003 May; 121(5):626-30. PubMed ID: 12742839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
